Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus + methotrexate
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sirolimus + methotrexate is a drug combination used primarily for graft-versus-host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation. Sirolimus is an mTOR inhibitor that suppresses T-cell activation and proliferation, while methotrexate is an antimetabolite that inhibits dihydrofolate reductase. When combined, these drugs have shown synergistic effects in preventing GVHD, particularly when used alongside tacrolimus. The combination has also demonstrated potential synergy in treating acute lymphoblastic leukemia (ALL), where it has shown promising results in preclinical studies.
- Other names
- Sirolimus and Methotrexate
02
Targets
DHFR (Dihydrofolate reductase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on sirolimus + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus + methotrexate.